Cyclerion Therapeutics (CYCN) Institutional Ownership $3.14 -0.16 (-4.85%) Closing price 05/2/2025 03:56 PM EasternExtended Trading$3.13 -0.01 (-0.32%) As of 05/2/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Cyclerion Therapeutics (NASDAQ:CYCN)CurrentInstitutional OwnershipPercentage75.62%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$34.17KNumber ofInstitutional Sellers(last 12 months)0 Get CYCN Insider Trade Alerts Want to know when executives and insiders are buying or selling Cyclerion Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CYCN Institutional Buying and Selling by Quarter Cyclerion Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/13/2025Renaissance Technologies LLC10,611$34K0.0%N/A0.392% 2/14/2024Tyndall Capital Partners L P164,429$551K100.0%+11.3%6.711% 11/14/2023Tyndall Capital Partners L P147,712$505K100.0%N/A6.129% 8/11/2023Artal Group S.A.138,955$572K0.0%-95.0%5.766% 5/9/2022Trustcore Financial Services LLC292,645$325K0.0%+47.7%0.674% 2/14/2022Diametric Capital LP100,480$173K0.1%+43.9%0.232% 2/10/2022Acadian Asset Management LLC249,792$428K0.0%N/A0.577% 11/16/2021Two Sigma Advisers LP647,700$1.99M0.0%+98.4%1.495% 11/16/2021Two Sigma Investments LP390,596$1.20M0.0%+154.1%0.902% 11/15/2021Pura Vida Investments LLC422,311$1.30M0.0%-16.8%0.975% Get the Latest News and Ratings for CYCN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/2021Eversept Partners LP371,955$1.14M0.1%N/A0.859% 11/15/2021Franklin Resources Inc.116,035$356K0.0%N/A0.268% 11/12/2021Jump Financial LLC52,000$160K0.0%N/A0.120% 11/12/2021Geode Capital Management LLC490,660$1.51M0.0%+27.5%1.134% 9/17/2021Virtu Financial LLC80,384$313K0.0%-9.2%0.186% 9/3/2021Parametric Portfolio Associates LLC12,596$49K0.0%-52.0%0.029% 8/25/2021Marshall Wace LLP28,863$113K0.0%N/A0.067% 8/18/2021Ikarian Capital LLC509,924$1.99M0.2%+70.0%1.178% 8/17/2021Millennium Management LLC389,041$1.52M0.0%N/A0.899% 8/17/2021Boothbay Fund Management LLC66,977$261K0.0%+96.3%0.155% 8/16/2021Cubist Systematic Strategies LLC17,084$67K0.0%N/A0.039% 8/16/2021Diametric Capital LP80,336$313K0.2%N/A0.186% 8/16/2021Slate Path Capital LP7,157,601$27.92M1.6%+15.5%16.539% 8/16/2021Charles Schwab Investment Management Inc.129,628$506K0.0%-35.1%0.300% 8/16/2021State Street Corp83,321$325K0.0%-79.2%0.193% 8/16/2021Tibra Equities Europe Ltd85,000$332K0.1%N/A0.196% 8/16/2021Goldman Sachs Group Inc.36,317$141K0.0%-9.4%0.084% 8/16/2021Marshall Wace LLP28,863$113K0.0%N/A0.067% 8/13/2021Renaissance Technologies LLC284,744$1.11M0.0%+22.1%0.658% 8/13/2021Northern Trust Corp64,616$252K0.0%-73.0%0.149% 8/13/2021Geode Capital Management LLC384,820$1.50M0.0%-21.0%0.889% 8/13/2021Vanguard Group Inc.1,423,532$5.55M0.0%-14.7%3.289% 8/13/2021FMR LLC2,674,811$10.43M0.0%-1.9%6.181% 8/12/2021Prime Capital Investment Advisors LLC22,250$87K0.0%N/A0.051% 8/12/2021XTX Topco Ltd17,968$70K0.0%+34.4%0.042% 8/12/2021Dimensional Fund Advisors LP158,994$620K0.0%+160.1%0.367% 8/12/2021JPMorgan Chase & Co.59,786$233K0.0%-43.7%0.138% 8/12/2021Ergoteles LLC96,100$375K0.0%N/A0.222% 8/11/2021 Bank of New York Mellon Corp66,792$260K0.0%-31.9%0.154% 8/11/2021Deutsche Bank AG65,900$257K0.0%-18.7%0.152% Here’s How to Claim Your Stake in Elon’s Private Company, xAI (Ad)I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.All the details are waiting for you now — but you need to act before the May 1st funding window clos8/11/2021Susquehanna Fundamental Investments LLC105,572$412K0.0%N/A0.244% 5/19/2021Virtu Financial LLC88,551$247K0.0%N/A0.259% 5/18/2021D. E. Shaw & Co. Inc.68,472$191K0.0%-62.2%0.201% 5/17/2021PDT Partners LLC42,900$120K0.0%+74.4%0.126% 5/17/2021Walleye Trading LLC10,000$28K0.0%N/A0.029% 5/17/2021Walleye Capital LLC15,000$42K0.0%N/A0.044% 5/17/2021Ikarian Capital LLC300,000$836K0.0%N/A0.879% 5/14/2021XTX Topco Ltd13,365$37K0.0%N/A0.039% 5/13/2021QS Investors LLC116,035$324K0.0%+13.1%0.340% 5/13/2021Barclays PLC18,516$52K0.0%+159.0%0.054% 5/13/2021Renaissance Technologies LLC233,200$651K0.0%+1,202.8%0.683% 5/12/2021Northern Trust Corp239,015$667K0.0%-7.0%0.700% 5/12/2021Geode Capital Management LLC486,959$1.36M0.0%+12.2%1.427% 5/12/2021JPMorgan Chase & Co.106,102$296K0.0%+19.1%0.311% 5/11/2021 New York State Common Retirement Fund12,070$34K0.0%-91.0%0.035% 5/10/2021Russell Investments Group Ltd.124,075$345K0.0%+400.2%0.363% 5/10/2021Bank Julius Baer & Co. Ltd Zurich12,000$33K0.0%-33.2%0.035% 5/7/2021BlackRock Inc.1,685,485$4.70M0.0%+5.1%4.938% 4/28/2021 DAVENPORT & Co LLC84,500$236K0.0%+369.0%0.248% 3/8/2021Dimensional Fund Advisors LP63,735$195K0.0%+8.7%0.187% 2/25/2021Dimensional Fund Advisors LP63,735$195K0.0%+8.7%0.188% 2/19/2021JPMorgan Chase & Co.89,079$273K0.0%+84.8%0.262% (Data available from 1/1/2016 forward) CYCN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CYCN shares? During the previous two years, the following institutional investors and hedge funds held shares of Cyclerion Therapeutics shares: Artal Group S.A. ($572K), and Tyndall Capital Partners L P ($551K), Renaissance Technologies LLC ($34K).Learn more on CYCN's institutional investors. What percentage of Cyclerion Therapeutics stock is owned by institutional investors? 75.62% of Cyclerion Therapeutics stock is owned by institutional investors. Learn more on CYCN's institutional investor holdings. Which institutional investors have been buying Cyclerion Therapeutics stock? The following institutional investors have purchased Cyclerion Therapeutics stock in the last 24 months: Tyndall Capital Partners L P ($164.43K), and Renaissance Technologies LLC ($10.61K). How much institutional buying is happening at Cyclerion Therapeutics? Institutional investors have bought a total of 175,040 shares in the last 24 months. This purchase volume represents approximately $595.34K in transactions. Which Cyclerion Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Cyclerion Therapeutics stock in the last 24 months: Artal Group S.A. ($2.64M). How much institutional selling is happening at Cyclerion Therapeutics? Institutional investors have sold a total of 2,640,167 shares in the last 24 months. This volume of shares sold represents approximately $10.85M in transactions. Related Companies FGEN Institutional Ownership INKT Institutional Ownership BRNS Institutional Ownership ALGS Institutional Ownership GBIO Institutional Ownership VYNE Institutional Ownership DARE Institutional Ownership CLNN Institutional Ownership TPST Institutional Ownership QTTB Institutional Ownership This page (NASDAQ:CYCN) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMassive red flag about American consumerWhy is the U.S. Dollar suddenly crashing? Pundits on either side of the aisle have been warning that the U....Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.